The U.S. Food and Drug Administration approved Zolgensma, a gene therapy that Novartis called a life-changing medicine, for children younger than 2 years of age who have been diagnosed with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 gene.
Indianapolis-based Eli Lilly announced that the company’s Lispro Injection, an authorized generic version of the life-saving insulin Humalog, is available at pharmacies at a 50 percent lower list price.
Opioid use has reached crisis proportions not only in the United States but also in Canada and some European countries, as prescription opioid painkillers have become much more common, the OECD club of wealthy nations said.
A Japanese government panel approved a price of 33.5 million yen ($305,800) for Novartis’ cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-start sluggish sales of the treatment.
England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.
Novartis said claims of price fixing against the drugmaker’s Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit.
Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.
U.S. President Donald Trump slammed the pharmaceutical industry for high prices of prescription drugs and vowed to allow U.S. states to buy medicines from other countries if they cost less.
The Trump administration will require drugmakers to disclose the list price of prescription drugs in DTC TV advertisements, part of the government’s efforts to lower costs for U.S. consumers.
Amgen Inc. set the U.S. list price for the company’s new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.